🔍

Jyothy Labs Limited (JYOTHYLAB)

📊 NSE: JYOTHYLAB 🏢 Personal Care - Indian 📅 Last Updated: 12/14/2025 8:44

📢 Recent Corporate Announcements

Jyothy Labs Schedules One-on-One Investor Meeting with MS Capital on September 11, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Sep 2026, 10:51 AM

Jyothy Labs Limited has informed exchanges of a scheduled one-on-one investor meeting with MS Capital on September 11, 2026. The meeting will be attended by company representatives, and no unpublished price-sensitive information (UPSI) is scheduled to be shared. The company noted that the current investor presentation is available on its website. This is a standard institutional interaction with no material financial impact.

One-on-one meeting scheduled with MS Capital on September 11, 2026
Intimation submitted under Regulation 30 of SEBI LODR Regulations, 2015
Company confirmed no Unpublished Price Sensitive Information (UPSI) will be shared
Current investor presentation referenced on company website

💡 Track subsequent post-meet disclosures or presentations filed on exchanges for any strategic or operational commentary.

Jyothy Labs Schedules One-on-One Investor Meeting with Mirabilis Investment Trust on Sep 10, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Sep 2026, 02:57 PM

Jyothy Labs Limited has informed the exchanges of a scheduled one-on-one meeting with Mirabilis Investment Trust on September 10, 2026. The company stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the interaction. This is a routine institutional investor engagement and carries no immediate financial impact for the Rs 7,136 crore market cap company.

One-on-one investor meeting scheduled for September 10, 2026
Meeting to be held with Mirabilis Investment Trust
No Unpublished Price Sensitive Information (UPSI) will be disclosed
Latest investor presentation is publicly available on the company website

💡 Track subsequent post-meet disclosures or investor presentations on the exchanges if any new operational insights are shared.

Jyothy Labs Grants 1.46 Lakh RSUs Under Employee Stock Unit Plan 2023

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Sep 2026, 06:27 PM

Jyothy Labs Limited has approved the grant of 1,46,141 Restricted Stock Units (RSUs) to eligible employees under its RSU Plan 2023 on September 4, 2026. Each RSU is convertible into one equity share of Re. 1 face value at an exercise price of Re. 1 per share. The units will vest over a period of 1 to 4 years subject to corporate performance conditions, with a 2-year exercise window post-vesting. The resulting equity expansion is negligible at less than 0.05% of the existing share capital.

Approved grant of 1,46,141 RSUs under RSU Plan 2023 on September 4, 2026
Exercise price set at face value of Re. 1 per equity share
Vesting timeline spans a minimum of 1 year to a maximum of 4 years
Vested RSUs exercisable within 2 years from vesting date

💡 This is a routine administrative grant; monitor standard quarterly financial performance and operating margins in upcoming earnings.

Jyothy Labs Schedules One-on-One Investor Meeting on September 8, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Sep 2026, 06:07 PM

Jyothy Labs Limited has informed the stock exchanges regarding a scheduled one-on-one investor meeting with Asit C. Mehta Investment Intermediates Ltd on September 8, 2026. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the interaction. This is a routine statutory disclosure under Regulation 30 of the SEBI LODR Regulations.

One-on-one meeting scheduled for September 8, 2026
Interaction scheduled with Asit C. Mehta Investment Intermediates Ltd
Company confirmed that no unpublished price sensitive information (UPSI) will be shared

💡 Track subsequent investor presentations or earnings releases for any updates on volume growth targets and rural distribution progress.

Jyothy Labs Schedules 1-on-1 Investor Meet with V.E.C Investment Management on Sept 8, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Sep 2026, 04:24 PM

Jyothy Labs Limited has disclosed a scheduled one-on-one institutional investor meeting with V.E.C Investment Management (India) Private Limited, slated for September 8, 2026. The company stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the meeting. Discussions will be based on publicly available information and investor presentations.

One-on-one interaction scheduled with V.E.C Investment Management (India) Private Limited
Meeting date fixed for September 8, 2026
No Unpublished Price Sensitive Information (UPSI) to be shared during the interaction

💡 This is a routine disclosure; investors should monitor quarterly performance and market share developments rather than individual investor meet schedules.

Jyothy Labs Assigned ESG Rating of '67' by NSE Sustainability Ratings for FY 2025-26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Sep 2026, 06:11 PM

NSE Sustainability Ratings & Analytics Limited has assigned an Environmental, Social, and Governance (ESG) rating of '67' to Jyothy Labs Limited for FY 2025-26. The evaluation was conducted independently using publicly available company data without a formal engagement by Jyothy Labs. The update is an administrative disclosure under Regulation 30 and has no direct financial or operational impact on the business.

Assigned an ESG score of '67' by NSE Sustainability Ratings & Analytics Limited
Rating is based on public domain data pertaining to FY 2025-26
Company clarified that it did not engage or commission the rating agency for this evaluation
Intimation received by the company on September 2, 2026

💡 Track core operational metrics including volume growth, raw material price pressures, and quarterly earnings performance, as this third-party ESG rating carries no immediate commercial impact.

Jyothy Labs Schedules One-on-One Analyst Meet with ICICI Securities for September 3, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Sep 2026, 02:43 PM

Jyothy Labs Limited has informed the exchanges of a scheduled one-on-one investor/analyst meeting with ICICI Securities on September 3, 2026. The meeting will be conducted under Regulation 30 of SEBI LODR Regulations. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during the interaction.

One-on-one meeting scheduled with ICICI Securities on September 3, 2026
Filing submitted pursuant to Regulation 30 of SEBI LODR Regulations, 2015
Company confirmed no Unpublished Price Sensitive Information (UPSI) will be shared

💡 Track the company's investor portal for any post-meet presentations or disclosures, as well as upcoming Q2 FY27 performance updates.

Jyothy Labs Receives Rs 20.35 Cr Excise Duty Demand Order; to File Appeal

🟡 NEUTRAL ⭐ 3/10

LEGAL 📅 25 Aug 2026, 11:28 AM

Jyothy Labs has received an Excise Duty Order from the CGST Commissionerate for the period April 2016 to June 2017 regarding an HSN product classification dispute. The order demands Rs 9.69 crore in excise duty, a redemption fine of Rs 9.69 crore, and a penalty of Rs 0.97 crore, plus applicable interest (totaling Rs 20.35 crore excluding interest). The total quantified demand represents approximately 5.9% of TTM PAT (Rs 342 crore) and 0.7% of TTM revenue (Rs 2,894 crore). The company intends to appeal, noting it previously received favorable orders on the identical classification issue at another location.

Received tax order demanding Rs 9.69 crore in excise duty and Rs 9.69 crore redemption fine
Additional penalty of Rs 0.97 crore plus applicable interest imposed for April 2016 to June 2017 period
Dispute pertains to product HSN classification interpretation under Central Excise Act
Total quantified demand of Rs 20.35 crore represents ~5.9% of TTM PAT (Rs 342 crore)
Management will appeal the order, citing previous favorable rulings accepted by authorities

💡 Monitor legal disclosures in upcoming quarterly reports for appellate progress or any potential contingent liability provisioning.

Q1 FY27 Call Transcript: EBITDA Margin Falls 820 bps to 8.4% on Raw Material Inflation

🔴 NEGATIVE ⭐ 5/10

EARNINGS 📅 14 Aug 2026, 06:47 PM

Jyothy Labs released the transcript of its Q1 FY27 earnings call, highlighting significant near-term margin pressure caused by crude-linked input cost inflation. Excluding the discontinued Pril business, revenue grew 8.1% in value and 5.3% in volume YoY, led by Fabric Care (+14% value, +10% volume). However, gross margin contracted 950 bps YoY to 38.5% and EBITDA margin dropped 820 bps YoY to 8.4% despite cutting A&P spending from 10.8% to 6.5% of revenue. Management expects H2 FY27 margins to improve progressively and reported a healthy net cash balance of approximately ₹850 crore.

Revenue growth (ex-Pril and FA) stood at 8.1% value and 5.3% volume YoY in Q1 FY27
EBITDA margin compressed by 820 bps YoY to 8.4%, flowing from a 950 bps drop in gross margin to 38.5%
Advertising & promotion (A&P) spend was trimmed to 6.5% of revenue versus 10.8% in Q1 FY26
Fabric Care segment outperformed with >14% value and 10% volume growth YoY
Net free cash balance reported at approximately ₹850 crore

💡 Track input cost trends (crude-linked derivatives and soap noodles) and management's margin recovery trajectory heading into H2 FY27.

Jyothy Labs Releases Audio Recording of Q1 FY27 Analyst Conference Call

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Aug 2026, 06:08 PM

Jyothy Labs has published the audio recording of its investor conference call held on August 12, 2026, regarding the financial results for the quarter ended June 30, 2026. The discussion likely centered on the company's strategy to maintain EBITDA margins of 16-17% and its volume-led growth strategy in rural markets. With a TTM revenue of ‡2,894 Cr and a direct reach of 1.2 million outlets, the call provides insights into how the company is navigating competitive pressures from MNCs. Investors can access the recording via the provided link to understand management's forward-looking commentary.

Conference call conducted on August 12, 2026, at 16:00 hours IST to discuss Q1 FY27 results.
Management continues to target an EBITDA margin range of 16-17% through operational efficiencies.
Company leverages a distribution network of 9,900+ channel partners and 2.8 million total retail outlets.
Focus remains on the 'van/moped model' to drive volume growth in rural markets, which saw 3.2% volume growth in previous periods.

💡 Investors should listen to the recording specifically for management's commentary on raw material price trends and the recovery of rural demand following previous GST-related disruptions.

Rs 9.93 Cr transfer of leasehold rights for Jammu manufacturing facility

🟡 NEUTRAL ⭐ 3/10

OTHER 📅 12 Aug 2026, 01:54 PM

Jyothy Labs has entered into an agreement to transfer the leasehold rights of its manufacturing facility in Jammu to Aikyam Flexipack Private Limited. The transaction is valued at approximately Rs 9.93 crores, which is less than 0.4% of the company's TTM revenue of Rs 2,894 crore. The facility, located in the SIDCO Industrial Complex, measures approximately 15 kanals. The deal is expected to conclude by March 31, 2027, subject to the fulfillment of mutually agreed conditions.

Transfer of leasehold rights for a consideration of approximately Rs 9.93 crores
Facility size measures approximately 15 kanals in Bari Brahmana, Jammu
Transaction expected to conclude on or before March 31, 2027
Buyer identified as M/s. Aikyam Flexipack Private Limited

💡 Investors should view this as a minor asset rationalization; watch for the final conclusion of the deal by March 2027 and any commentary on manufacturing footprint optimization in upcoming quarterly calls.

50.8% PAT Drop in Q1 FY27 as Gross Margins Contract to 38.5%

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 01:41 PM

Jyothy Labs reported a weak Q1 FY27 with PAT declining 50.8% YoY to ₹47.6 Cr, primarily driven by a sharp contraction in gross margins from 48% to 38.5%. While headline revenue grew 3% to ₹773 Cr, underlying growth (excluding divested brands Pril & Fa) was healthier at 8.1% value and 5.3% volume. Operating EBITDA fell 47.9% to ₹64.7 Cr as raw material inflation and packaging costs pressured the bottom line. The company has restructured its reporting into three segments: Fabric Care, Home Care, and Personal Care.

Net Profit (PAT) declined by 50.8% YoY to ₹47.6 Cr for the quarter ended June 30, 2026
Gross margins contracted by 950 basis points to 38.5% due to raw material and packaging cost inflation
Excluding discontinued brands Pril & Fa, value growth stood at 8.1% with volume growth at 5.3%
Fabric Care segment led growth with a 14.1% YoY increase to ₹399 Cr
Operating EBITDA margin halved to 8.4% from 16.5% in the previous year's corresponding quarter

💡 Monitor the trajectory of crude-linked raw material prices and the company's ability to pass on costs through pricing. Watch the scaling of new launches like Maxo Agarbatti and Exo Liquid to see if they can improve the margin profile in upcoming quarters.

₹773 Cr Revenue in Q1 FY27; EBITDA Margins Contract to 8.4% Amid Commodity Inflation

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 01:19 PM

Jyothy Labs reported a modest 3.0% YoY revenue growth to ₹773 crore for Q1 FY27, though its core portfolio (excluding Pril and Fa) showed stronger resilience with 8.1% value growth. Profitability was significantly impacted by elevated crude-linked input costs and commodity inflation, causing Operating EBITDA margins to drop to 8.4%, well below the TTM average of 16.1%. PAT for the quarter stood at ₹47.6 crore, representing approximately 14% of the TTM PAT. While the Fabric Care segment performed well with 10.2% volume growth, urban demand remains subdued.

Revenue reached ₹773 crore, a 3.0% value growth compared to the same quarter last year.
Core portfolio (excluding Pril and Fa) delivered 5.3% volume growth and 8.1% value growth.
Operating EBITDA margin contracted sharply to 8.4% from historical levels due to input cost volatility.
Fabric Care segment led growth with 14.1% value growth and 10.2% volume growth.
Profit After Tax (PAT) for the quarter was reported at ₹47.6 crore.

💡 Investors should monitor the trend of crude-linked raw material prices and the company's ability to implement 'calibrated pricing actions' to recover margins. The key metric to watch in the next quarter is whether EBITDA margins stabilize back toward the 15-16% range.

50.8% PAT drop in Q1 FY27 as EBITDA margins contract to 8.4% on input cost inflation

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 01:15 PM

Jyothy Labs reported a significant decline in profitability for Q1 FY27, with PAT falling 50.8% YoY to ₹47.6 Cr. While revenue grew 3% to ₹773 Cr, Operating EBITDA margins collapsed from 16.5% to 8.4% due to a 950 bps drop in gross margins caused by abnormal raw material inflation. Excluding the impact of the Pril and Fa brands (discontinued after May 2026), underlying value growth was healthier at 8.1% with volume growth of 5.3%. The company has restructured its reporting into three segments: Fabric Care, Home Care, and Personal Care.

PAT declined by 50.8% YoY to ₹47.6 Cr from ₹96.8 Cr in the same quarter last year.
Operating EBITDA margin compressed to 8.4% from 16.5% YoY, driven by a 9.5% hit to gross margins.
Gross margins fell to 38.5% compared to 48.0% in Q1 FY26 due to crude-linked input inflation.
Fabric Care segment grew 14.1% YoY to ₹399 Cr, while Home Care (including Pril) declined 9.0%.
Direct reach expanded to 1.4 million outlets with total availability across 4 million outlets.

💡 Investors should monitor the trajectory of raw material prices and the company's ability to implement price hikes to recover margins. The key execution metric will be the successful scaling of new launches like Maxo Agarbatti and Exo Dishwash Liquid to fill the revenue gap left by the Pril and Fa brands.

₹47.64 Cr Q1 Net Profit: Jyothy Labs Profit Drops 50.8% YoY Amid Rising Material Costs

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 01:04 PM

Jyothy Labs reported a modest 2.95% YoY revenue growth to ₹773.40 Cr for Q1 FY27, but net profit plummeted 50.8% to ₹47.64 Cr from ₹96.79 Cr in the year-ago period. The primary headwind was a 49.9% surge in material costs, which reached ₹530.33 Cr, significantly compressing margins. While the Fabric Care segment showed resilience with 14.1% revenue growth, the Home Care segment's profitability crashed by 82.4% YoY. Basic EPS for the quarter halved to ₹1.30 compared to ₹2.64 in Q1 FY26.

Net Profit fell 50.8% YoY to ₹47.64 Cr from ₹96.79 Cr in Q1 FY26.
Cost of materials consumed surged by 49.9% to ₹530.33 Cr, representing 68.6% of revenue.
Fabric Care revenue grew 14.1% YoY to ₹398.89 Cr, remaining the largest segment.
Home Care segment PBIT collapsed to ₹8.14 Cr from ₹46.27 Cr in the corresponding previous quarter.
Total expenses rose 12.9% YoY to ₹726.07 Cr despite only 2.95% revenue growth.

💡 Investors should monitor management's commentary regarding raw material price volatility and their ability to implement price hikes to restore margins. The sharp decline in Home Care profitability is a key area of concern for the next few quarters.

View All JYOTHYLAB Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In FY 2024-25, Fabric Care grew 5.0% (44% of revenue), Dishwashing grew 3.7% (34% of revenue), Household Insecticides declined 6.5% (7% of revenue), Personal Care declined 0.9% (11% of revenue), and Others grew 10.8% (4% of revenue). For H1 FY26, the company reported 1% value growth and 3.2% volume growth.

Geographic Revenue Split

Not disclosed in available documents, though the company maintains a pan-India presence with 23 manufacturing facilities and a strong focus on rural-driven growth.

Profitability Margins

Gross margin for H1 FY26 stood at 48%, a contraction from 50.8% in H1 FY25 due to input cost pressures. PAT margin for FY24 was 13.3% (INR 369.3 Cr on INR 2,767.2 Cr revenue).

EBITDA Margin

Operating EBITDA margin was 17.5% in FY25 (INR 500 Cr) compared to 17.4% in FY24 (INR 480 Cr). However, H1 FY26 saw a decline to 16.3% from 18.4% in the previous year due to higher operating costs and commodity fluctuations.

Capital Expenditure

The company is expected to remain debt-free as there are no major debt-funded capital expenditure plans. Cash and bank balances including investments increased to INR 757 Cr in FY25 from INR 618 Cr in FY24.

Credit Rating & Borrowing

CARE Ratings reaffirmed 'CARE AA; Stable' for long-term bank facilities (INR 250 Cr) and 'CARE A1+' for Commercial Paper (INR 100 Cr, later withdrawn as unutilized). The company operates with minimal finance costs of INR 6 Cr (FY25).

⚙️ Operational Drivers

Raw Materials

Key inputs include chemicals for detergents (Fabric Care), raw materials for soaps (Personal Care), and materials for insecticide coils. Specific commodity names like palm oil or LAB are not explicitly listed but are categorized as 'input costs' and 'commodities'.

Capacity Expansion

The company operates 23 state-of-the-art manufacturing facilities across India. Specific MTPA capacity figures or planned expansion units are not detailed in the provided text.

Raw Material Costs

Cost of Goods Sold (COGS) was INR 1,419 Cr in FY25, representing 49.8% of revenue, a slight increase of 1.1% YoY from INR 1,404 Cr.

Manufacturing Efficiency

The company focuses on economies of scale and productivity improvements to balance competitive pricing with profitability.

Logistics & Distribution

Advertisement and sales promotion costs were INR 240 Cr in FY25 (8.4% of net sales), used to support a distribution network reaching 1.2 million outlets directly.

📈 Strategic Growth

Expected Growth Rate

3.20%

Growth Strategy

Growth will be driven by volume-led expansion in rural markets using the van/moped model, scaling premium product launches, and leveraging digital/modern trade channels. The company aims to maintain an EBITDA margin of 16-17% through better mix management and scaling innovations.

Products & Services

Fabric whiteners, detergent powders, detergent bars, liquid detergents, dishwash bars, dishwash liquids, household insecticide coils, and personal care soaps.

Brand Portfolio

Ujala, Maxo, Exo, Henko, Pril, Margo, and Mr. White.

New Products/Services

Focus on liquid detergents (main growth driver for Fabric Care) and organic/natural products developed through R&D.

Market Expansion

Expansion of direct reach to 1.2 million outlets and total availability in 2.8 million outlets, focusing on rural-driven growth and modern trade/e-commerce.

Market Share & Ranking

Ujala commands a dominant position in the fabric care (whitener) segment; the company is a prominent pan-India FMCG player.

Strategic Alliances

Merged Jyothy Fabricare Services Ltd (JFSL) into the parent company and divested its 75% equity stake in Jyothy Kallol Bangladesh Limited (JKBL) as of March 25, 2025.

🌍 External Factors

Industry Trends

The FMCG sector is seeing a measured recovery driven by affordability and easing cost pressures, with a shift toward digital channels and premiumization.

Competitive Landscape

Operates in a fiercely competitive and price-sensitive industry dominated by MNCs with larger diversified portfolios.

Competitive Moat

Strong brand equity (Ujala), a massive distribution network (2.8m outlets), and a debt-free balance sheet provide a durable competitive advantage against smaller players.

Macro Economic Sensitivity

Highly sensitive to rural sentiment and inflation; a median population age of 27 and government financial inclusion initiatives are expected to drive exponential consumption growth.

Consumer Behavior

Increasing consumerism and rising aspirations among India's young population are driving demand for cleaning and hygiene solutions.

Geopolitical Risks

Global uncertainties continue to pose challenges to input costs and supply chain stability.

⚖️ Regulatory & Governance

Industry Regulations

Impacted by GST rate revisions (September 2025) which caused a 13% advantage for some distributors through input credit but disrupted short-term market flow.